Lucid Diagnostics (LUCD) Shares Outstanding (2020 - 2026)

Lucid Diagnostics (LUCD) has 7 years of Shares Outstanding data on file, last reported at $164.9 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 95.41% year-over-year to $164.9 million; the trailing twelve-month figure through Mar 2026 stood at $164.9 million (up 95.41% YoY), and the FY2025 full-year result was $131.1 million, up 240806.23% from the prior year.
• Shares Outstanding for Q1 2026 stood at $164.9 million, up from $131.1 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $164.9 million in Q1 2026 and bottomed at $13625.0 in Q2 2023.
• The 5-year median for Shares Outstanding is $37.0 million (2022), against an average of $39.4 million.
• The widest annual swing landed in 2023, when Shares Outstanding plunged 99.96%; it then soared 342997.7% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $40.5 million in 2022, then sank by 99.95% to $18625.0 in 2023, then surged by 192.18% to $54419.0 in 2024, then surged by 240806.23% to $131.1 million in 2025, then increased by 25.77% to $164.9 million in 2026.
• The last three Shares Outstanding figures came in at $164.9 million (Q1 2026), $131.1 million (Q4 2025), and $130.9 million (Q3 2025), per Business Quant data.

Peer Comparison